Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
about
The role of magnetic resonance imaging in the diagnosis and management of prostate cancerManagement of low (favourable)-risk prostate cancerProstate cancer--to screen, or not to screen, is that the question?Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancerImportance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.Integrated predictive model for prostatic cancer using clinical, laboratory and ultrasound data.Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerOverdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerFormalized prediction of clinically significant prostate cancer: is it possible?Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study.Why can't nomograms be more like Netflix?Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study.Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer.Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study
P2860
Q26849794-C328638B-9BB8-413A-8742-12A8F2CE49D9Q26996501-7D5B3E64-63BE-4719-8157-845A355E656CQ33395534-CA8424C9-DFEA-48A5-A228-6E7C905F1C34Q33567004-BBAF265F-4210-483D-AB53-ED3D33535A03Q35722781-715835F3-B3C3-4C88-81AD-C4DBB94A038CQ35875135-9D433E26-03B9-4E21-8052-E6E85398B226Q36300978-D6782782-276C-4C1B-8D5E-D7A16E132D21Q36421154-0CCCB49E-4A64-4F07-A956-ED59D636EDC4Q37307609-F625A4CB-D934-44E7-8651-D99955C2D864Q37422990-E61E88E1-5A91-42AE-A46B-127A9E23E4A7Q37457676-191866BE-E443-455A-B289-12AF3BED5487Q37988363-410820EB-6FA9-4D25-AB0F-A5C42824F144Q38211619-BC8CD4F7-8423-4431-8E4C-E60263ECBB86Q39532018-BE04019C-01DB-46C8-8D32-4067D74E5D92Q41599088-7626B027-7628-419F-8168-C562DCFE1CE2Q43914035-54F11BEE-87A2-49BE-BAD2-30395685029CQ46873257-57A1BAB1-D299-4EAC-A568-24D93A5324D6Q57259807-A117C1F1-1320-460A-A411-7D115DC52275
P2860
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Validation of pretreatment nom ...... temporary urological practice.
@en
Validation of pretreatment nom ...... temporary urological practice.
@nl
type
label
Validation of pretreatment nom ...... temporary urological practice.
@en
Validation of pretreatment nom ...... temporary urological practice.
@nl
prefLabel
Validation of pretreatment nom ...... temporary urological practice.
@en
Validation of pretreatment nom ...... temporary urological practice.
@nl
P2093
P1476
Validation of pretreatment nom ...... temporary urological practice.
@en
P2093
Andrew J Stephenson
Eric A Klein
Fritz H Schröder
J Stephen Jones
Michael W Kattan
P304
150-4; discussion 154
P356
10.1016/J.JURO.2008.03.053
P407
P577
2008-05-15T00:00:00Z